Posted by Michael Wonder on 19 Jun 2018
Patients call for end to two-year row over cystic fibrosis drug funding
19 June 2018 - UK patients are stepping up efforts to resolve the “heartbreaking” row that is denying their families access to Vertex’s groundbreaking cystic fibrosis drug Orkambi, after Sweden became the latest European country to reimburse it.
Vertex has reached an agreement with the Swedish health system to reimburse Orkambi, the first medicine to treat the underlying cause of cystic fibrosis in people with two copies of the F508del mutation, aged six or over.
Reimbursement will begin from July 1, and the access agreement provides a framework for the assessment and access of future cystic fibrosis drugs, Vertex said.
